Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 30.69 CNY 0.39%
Market Cap: 5.4B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chengdu Easton Biopharmaceuticals Co Ltd
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Other Receivables
ÂĄ62.2m
CAGR 3-Years
9%
CAGR 5-Years
33%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Receivables
ÂĄ111m
CAGR 3-Years
-38%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Receivables
ÂĄ297.6m
CAGR 3-Years
19%
CAGR 5-Years
8%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Receivables
ÂĄ1.3B
CAGR 3-Years
-23%
CAGR 5-Years
3%
CAGR 10-Years
0%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Receivables
ÂĄ3.1B
CAGR 3-Years
33%
CAGR 5-Years
-10%
CAGR 10-Years
-2%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Receivables
ÂĄ74.5m
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chengdu Easton Biopharmaceuticals Co Ltd
Glance View

Market Cap
5.4B CNY
Industry
Pharmaceuticals

Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan and currently employs 1,188 full-time employees. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.

Intrinsic Value
50.9 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Other Receivables?
Other Receivables
62.2m CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Other Receivables amounts to 62.2m CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Other Receivables growth rate?
Other Receivables CAGR 5Y
33%

Over the last year, the Other Receivables growth was 13%. The average annual Other Receivables growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been 9% over the past three years , 33% over the past five years .

Back to Top